Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02717195 · ClinicalTrials.gov registry record · Phase 3
Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia
A Phase 3 study, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,098
- Enrollment target
NCT02717195: Completed Phase 3 study, sponsored by H. Lundbeck A/S.
NCT02717195 is a Phase 3 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 1,098 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02717195, a Phase 3 study, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,098 participants
- Enrollment target
Study Summary
To evaluate the efficacy of 10 and 20 mg/day of Lu AF35700 on schizophrenia symptoms in patients with treatment-resistant schizophrenia (TRS)
Primary Outcome
PANSS total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia.
Interventions
- DRUG Risperidone
- DRUG Olanzapine
- DRUG Lu AF35700
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,098 participants |
| Start Date | 2016-04 |
| Est. Completion | 2018-10-08 |
| Phase | Phase 3 |
What the finished NCT02717195 record still lists
NCT02717195 is an interventional study that assigns participants to a tested intervention. Its 1,098 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% higher).
The record links to 0 conditions, and to 3 interventions - of which Risperidone is the first listed.
NCT02717195 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02717195 about?
NCT02717195 is a clinical study titled "Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia". To evaluate the efficacy of 10 and 20 mg/day of Lu AF35700 on schizophrenia symptoms in patients with treatment-resistant schizophrenia (TRS)
What is the current status of trial NCT02717195?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,098 participants. The study started on 2016-04. Estimated completion is 2018-10-08.
What interventions are being tested in trial NCT02717195?
The interventions under investigation include: Risperidone (DRUG), Olanzapine (DRUG), Lu AF35700 (DRUG).
Who is sponsoring clinical trial NCT02717195?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02717195's enrollment target sits among peer trials
1,098 265th of 2000 higher than 1,736 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
- NCT05638581 · 1,100 participants · Phase 3
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia